|
 |
DATE: January 4, 2005
SUBJECT: RTOG 88-15, Terminated
Terminated
RTOG 88-15, (INT 0096, EST 3588, SWOG 8991) "A Phase III Study of Cisplatin Plus Etoposide Combined with Standard Fractionation Thoracic Radiotherapy Versus Cisplatin Plus Etoposide Combined With Multiple Daily Fractionated Thoracic Radiotherapy For Limited Stage Small Cell Lung Cancer", has been terminated, effective today, 1/4/05. All study activity and data collection has ceased, and the study should be terminated at your local IRB. Any data received after this date will be returned.
To share a comment or ask a question, access the Headquarters Information and Telephone Listing on the RTOG web site, www.rtog.org, under "Member Info", or call 1-800-227-5463, ext. 4189, which provides a menu to reach the Headquarters departments. If you would like to be added/removed from the RTOG broadcast list or wish to update your e-mail address, contact David Corrie at dcorrie@phila.acr.org.
Web registration is available 24/7. Information and instructions are at https://silver1.phila.acr.org/Clinical_RTOG/pgIndex.html
|
|
|
